Response to imatinib as a function of target kinase expression in recurrent glioblastoma

BACKGROUND: Despite some progress in the treatment of glioblastoma, most patients experience tumor recurrence. Imatinib mesylate, a tyrosine kinase inhibitor of platelet derived growth factor receptor-alpha and -beta, c-fms, c-kit, abl and arg kinase (imatinib targets), has been shown to prevent tum...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Springerplus
Main Authors: Hassler, Marco Ronald, Vedadinejad, Mariam, Flechl, Birgit, Haberler, Christine, Preusser, Matthias, Hainfellner, Johannes Andreas, Wöhrer, Adelheid, Dieckmann, Karin Ute, Rössler, Karl, Kast, Richard, Marosi, Christine
Formato: Artigo
Idioma:Inglês
Publicado: Springer International Publishing 2014
Assuntos:
Short Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4320134/
https://ncbi.nlm.nih.gov/pubmed/25674429
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2193-1801-3-111
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares